Search clinical trials for: Oxycodone Immediate-Release

Total 6496 results

Pfizer

Completed

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Healthy

United States
University of Rochester

Terminated

Open-Label Trial Comparing Oxycodone Medications (OUTCOMES)

Chronic Pain

United States
Ensysce Biosciences
Dr. Vince Clinical Research

Completed

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Recreational Drug Use

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Prescription Opioid Effects in Abusers Versus Non-Abusers

Substance-Related Disorders | Opioid-Related Disorders

United States
Ensysce Biosciences

Completed

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Recreational Drug Use

United States
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Oxycodone User Registry (OUR)

Pain
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Back Pain Lower Back Chronic

United States
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Osteoarthritis

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Brigham and Women's Hospital
National Institute on Drug Abuse (NIDA)

Active, not recruiting

Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain

Low Back Pain

United States
Egalet Ltd

Completed

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Moderate-to-severe Chronic Low Back Pain

United States
Cephalon

Completed

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

Chronic Pain

United States
Cephalon

Completed

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

Chronic Pain

United States
Mundipharma Research GmbH & Co KG

Completed

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Chronic Osteoarthritis

Spain, Belgium, Finland, Czechia, Germany, Hungary
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Mayo Clinic

Completed

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

Healthy

United States
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy

Pain | Constipation

United Kingdom
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Kuopio University Hospital
Admescope Ltd

Active, not recruiting

The Safety and Efficacy of Epidural Oxycodone (epioksipanu)

Pain, Postoperative

Finland
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Vanderbilt University Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

Pain | Analgesia | Abuse Opioids

United States
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Kuopio University Hospital
Admescope Ltd

Recruiting

Oxycodone in Treatment of Early Labour Pain Efficacy and Safety (oksisynnytys)

Labor Pain

Finland
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Egalet Ltd

Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Moderate-to-severe Chronic Noncancer Pain

United States
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Rigshospitalet, Denmark
Karolinska Institutet; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Recruiting

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

CLL

Denmark, Sweden, Netherlands
Mundipharma Research GmbH & Co KG

Completed

A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain

Subjects With Moderate to Severe, Chronic Nonmalignant Pain
Tulane University
National Institute of General Medical Sciences (NIGMS)

Completed

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial (NICE)

Chronic Kidney Disease

United States
Purdue Pharma LP

Completed

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Opioid Analgesia

United States, Australia, Finland, New Zealand
Tan Tock Seng Hospital

Completed

Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain

Postcraniotomy Pain

Singapore
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted

Healthy

Belgium
Purdue Pharma LP

Completed

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Pain

United States, Israel
University of California, Los Angeles
Tulane University; Los Angeles LGBT Center

Active, not recruiting

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

Human Immunodeficiency Virus

United States
Elcelyx Therapeutics, Inc.

Completed

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Type 2 Diabetes Mellitus

United States

3

Subscribe